Skip to main content
. 2021 Mar 1;13(5):1015. doi: 10.3390/cancers13051015

Table 2.

Comparison of trastuzumab–emtansine (T-DM1) vs. trastuzumab–duocarmazine (SYD−986) vs. trastuzumab–deruxtecan (T-Dxd).

Antibody-Drug Conjugate T-DM1 SYD-986 T-Dxd
HER2 targeting vehicle Trastuzumab Trastuzumab Trastuzumab
Linker Non-cleavable Cleavable Cleavable
Drug–antibody ratio 3.5:1 2.8:1 8:1
Cytotoxic moiety Maytansine derivative Seco-DUBA Exatecan derivative
Cytotoxic moiety MoA Antimicrotubule (mitotic poison) Alkylating agent Topoisomerase I inhibitor
Diffusible cytotoxic moiety? graphic file with name cancers-13-01015-i001.jpg graphic file with name cancers-13-01015-i001.jpg graphic file with name cancers-13-01015-i002.jpg
Bystander killing effect? graphic file with name cancers-13-01015-i001.jpg graphic file with name cancers-13-01015-i002.jpg graphic file with name cancers-13-01015-i002.jpg
Targets HER2-positive or homogenous tumors? graphic file with name cancers-13-01015-i002.jpg graphic file with name cancers-13-01015-i002.jpg graphic file with name cancers-13-01015-i002.jpg
Targets HER2-low or heterogeneous tumors? graphic file with name cancers-13-01015-i001.jpg graphic file with name cancers-13-01015-i002.jpg graphic file with name cancers-13-01015-i002.jpg

Legend: MoA = mechanism of action.